Alzheimer’s disease is notorious for robbing individuals of memory and cognitive function. Researchers have struggled for ...

Delve into how the biotech industry is pivoting from the amyloid hypothesis to find new Alzheimer's disease treatments.

A recent study revealed that an experimental blood test for Alzheimer’s disease not only can help in accurate diagnosis but ...

Buoyed by new results from a phase 1b/2a trial, Roche has said it plans to start a phase 3 programme for an Alzheimer's ...

Biomarker and cognitive data supported treatment with the anti-amyloid agent lecanemab (Leqembi) for up to 36 months in early ...

There's still so much we don't know about Alzheimer's disease, but the link between poor sleep and worsening disease is one ...

Roche has reported preliminary results on its Alzheimer’s disease prospect trontinemab. | Roche has reported preliminary ...

which has just completed enrolment in a phase III trial of a tau-targeting drug in mild-to-moderate AD. Despite an R&D spend of around $15bn, a total of 20 beta amyloid protein-targeting drugs ...

Roche Holdings AG (OTC:RHHBY) on Thursday presented new data at the AD/PD 2025 International Conference on Alzheimer’s and ...

“This blood test clearly identifies Alzheimer’s tau tangles, which is our best biomarker measure of Alzheimer’s symptoms and ...

Encouraging interim results have supported Roche’s decision to move trontinemab into a pivotal Phase III programme.